Company Overview: Moleculin

Industry News

18 Jul

Moleculin Signs Agreement with MD Anderson Cancer Center for Leukemia Drug, Annamycin

HOUSTON, TX–(Marketwired – July 18, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it...

Read more

12 Jul

Moleculin Regains Compliance with NASDAQ Listing Requirements

HOUSTON, TX–(Marketwired – July 12, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that...

Read more

29 Jun

Reminder: Moleculin Announces Conference Call to Discuss Recent New Discovery for Pancreatic Cancer and Business Update

HOUSTON, TX–(Marketwired – June 29, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a...

Read more

26 Jun

Moleculin Announces Scientific Support for Research Endeavor at Mayo Clinic

HOUSTON, TX–(Marketwired – June 26, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it...

Read more

21 Jun

Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer

HOUSTON, TX–(Marketwired – June 21, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center,...

Read more

1 Jun

Moleculin Biotech to Present at Upcoming Investor Conferences

HOUSTON, TX–(Marketwired – June 01, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address